PLSE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pulse Biosciences Inc (PLSE) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. The stock lacks immediate positive trading signals, faces insider selling pressure, and its financial performance remains weak. While there are promising developments in its pipeline and analyst optimism, the lack of current profitability and technical weakness suggest holding off on investment for now.
The MACD is negative and expanding (-0.356), indicating bearish momentum. RSI is neutral at 32.455, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 18.957, with resistance at 23.052. Overall, the technical indicators suggest weakness.
FDA approval to commence pivotal IDE study for nPulse Cardiac Catheter.
Positive analyst sentiment with raised price targets to $
Enrollment of first patients in NANOPULSE-AF study.
Insiders are selling heavily, with a 3340.02% increase in selling over the last month.
Weak financial performance in Q4 2025, with a net income drop of -10.07% YoY and EPS decline of -16.13% YoY.
No significant hedge fund activity and neutral sentiment.
In Q4 2025, revenue remained flat at $264,000 (0.00% YoY growth). Net income dropped to -$17.43M (-10.07% YoY), and EPS fell to -0.26 (-16.13% YoY). Gross margin remained unchanged at 1.52.
Analysts are optimistic, with Oppenheimer and Mizuho raising price targets to $30. Both firms maintain Outperform ratings, citing strong technology potential and encouraging feasibility data. However, the success depends on larger trials and adoption.
